Navignostics

Navignostics is a private, early-stage diagnostics company leveraging a proprietary spatial single-cell proteomics platform to enable precision cancer medicine. Its core technology, Imaging Mass Cytometry, allows for the simultaneous analysis of up to 50 protein markers on a single standard tissue section, providing detailed maps of the tumor microenvironment. The company operates a service-based business model, partnering with clinicians for treatment selection and with pharmaceutical companies for biomarker discovery and patient stratification in clinical trials. Recent awards and a notable publication in Nature Medicine underscore its technological validation and growing industry recognition.

Spatial single-cell proteomics platform combining highly multiplex protein imaging (Imaging Mass Cytometry) with advanced computational analytics to analyze up to 50 protein markers simultaneously on standard FFPE tissue sections.

Navignostics competes in the spatial biology and multiplex diagnostics space. Direct competitors include other IMC service providers and companies like Akoya Biosciences (multiplex immunofluorescence). It faces broader competition from large diagnostic players (e.g., Roche, Agilent) developing their own multiplex assays and numerous digital pathology AI firms.